Succinobucol

Succinobucol (AGI-1067) is a metabolite and derivative of probucol with antioxidant and anti-inflammatory properties. It has been investigated for cardiovascular protection, particularly in atherosclerosis and acute coronary syndrome. Mediocon Inc supplies pharmaceutical-grade Succinobucol conforming to IP / BP / EP / USP specifications.

As a potent antioxidant, Succinobucol inhibits LDL oxidation and reduces vascular inflammation. It has been studied in clinical trials for its cardioprotective effects.

Key Features

• High-purity pharmaceutical grade API
• IP / BP / EP / USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing facility

Applications

• Cardiovascular research formulations
• Antioxidant drug development
• Atherosclerosis studies
• Anti-inflammatory research

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings

Parameter	Specification
Assay	NLT 98.0%
Loss on Drying	NMT 0.5%
Heavy Metals	NMT 20 ppm
Residue on Ignition	NMT 0.1%
Microbial Limits	Complies with pharmacopoeia
Identification	IR, HPLC Compliant
Mfg Date	MAR 2025
Exp Date	FEB 2031
Packing	25 kg HDPE drums / as per requirement